收费全文 | 199篇 |
免费 | 8篇 |
财政金融 | 45篇 |
工业经济 | 14篇 |
计划管理 | 25篇 |
经济学 | 55篇 |
综合类 | 1篇 |
运输经济 | 2篇 |
贸易经济 | 40篇 |
农业经济 | 3篇 |
经济概况 | 11篇 |
邮电经济 | 11篇 |
2022年 | 2篇 |
2021年 | 1篇 |
2020年 | 7篇 |
2019年 | 4篇 |
2018年 | 6篇 |
2017年 | 8篇 |
2016年 | 9篇 |
2015年 | 6篇 |
2014年 | 7篇 |
2013年 | 14篇 |
2012年 | 12篇 |
2011年 | 13篇 |
2010年 | 13篇 |
2009年 | 16篇 |
2008年 | 13篇 |
2007年 | 7篇 |
2006年 | 5篇 |
2005年 | 6篇 |
2004年 | 3篇 |
2003年 | 6篇 |
2002年 | 2篇 |
2001年 | 4篇 |
2000年 | 2篇 |
1999年 | 7篇 |
1998年 | 1篇 |
1997年 | 4篇 |
1996年 | 1篇 |
1994年 | 4篇 |
1993年 | 2篇 |
1992年 | 1篇 |
1990年 | 3篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1985年 | 1篇 |
1984年 | 1篇 |
1983年 | 2篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1978年 | 1篇 |
1977年 | 4篇 |
1973年 | 2篇 |
1967年 | 1篇 |
Materials and methods: This study utilized the Surveillance Epidemiology and End Results (SEER) cancer registry linked to Medicare claims records. The study population included all SEER-Medicare patients diagnosed in 2008–2009 with advanced non-squamous NSCLC (stages IIIB–IV) as their only primary cancer and who started chemotherapy within 90 days of diagnosis. The study evaluated the four most commonly observed first-line regimens: paclitaxel/carboplatin, platinum monotherapy, pemetrexed/platinum, and paclitaxel/carboplatin/bevacizumab. Overall survival and total healthcare cost comparisons as well as incremental cost-effectiveness ratios (ICERs) were calculated for pemetrexed/platinum vs each of the other three. Unstratified analyses and analyses stratified by initial disease stage were conducted.
Results: The final study population consisted of 2,461 patients. Greater administrative censorship of pemetrexed recipients at the end of the study period disproportionately reduced the observed mean survival for pemetrexed/platinum recipients. The disease stage-stratified ICER analysis found that the pemetrexed/platinum incurred total Medicare costs of $536,424 and $283,560 per observed additional year of life relative to platinum monotherapy and paclitaxel/carboplatin, respectively. The pemetrexed/platinum vs triplet comparator analysis indicated that pemetrexed/platinum was associated with considerably lower total Medicare costs, with no appreciable survival difference.
Limitations: Limitations included differential censorship of the study regimen recipients and differential administration of radiotherapy.
Conclusions: Pemetrexed/platinum yielded either improved survival at increased cost or similar survival at reduced cost relative to comparator regimens in the treatment of advanced non-squamous NSCLC. Limitations in the study methodology suggest that the observed pemetrexed survival benefit was likely conservative. 相似文献